Liver cancer

Clinics in Liver Disease

Volumn 5, Issue 2, 2001, Pages 479-508

  Aguayo, Alvaro ^a   Patt, Yehuda Z ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 DIMETHYLAMINOETHYL) 9 METHOXY 5 NITROPYRAZOLO[3,4,5 KL]ACRIDINE; ALPHA INTERFERON; ALPHA2 INTERFERON; AMIFOSTINE; AMSACRINE; BETA INTERFERON; CAPECITABINE; CISPLATIN; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUOROURACIL; FOLINIC ACID; FUMAGILLOL CHLOROACETYLCARBAMATE; GEMCITABINE; IFOSFAMIDE; INTERFERON; MITOXANTRONE; OCTREOTIDE; POLYPRENOIC ACID; RETINOID; TAMOXIFEN; TEGAFUR; THALIDOMIDE; URACIL;

CANCER PREVENTION; CANCER SURGERY; CANCER SURVIVAL; CLINICAL RESEARCH; CLINICAL TRIAL; FATIGUE; HUMAN; LIVER CANCER; LIVER CARCINOGENESIS; MUCOSA INFLAMMATION; PROGNOSIS; REVIEW; SURVIVAL TIME; VACCINATION; VIRUS HEPATITIS;

EID: 0035006751     PISSN: 10893261     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1089-3261(05)70175-6     Document Type: Review

References (196)

1. A.A. Adjei Current status of pyrazoloacridine as an anticancer agent Invest New Drugs 17 1999 43
2. M.H. Ahmed H. Konno L. Nahar The angiogenesis inhibitor TNP-470 (AGM-1470) improves long-term survival of rats with liver metastasis J Surg Res 64 1996 35
3. E.A. Akriviadis J.M. Llovet S.C. Efremidis Hepatocellular carcinoma Br J Surg 85 1998 1319
4. F.Q. An M. Matsuda H. Fujii Expression of vascular endothelial growth factor in surgical specimens of hepatocellular carcinoma J Cancer Res Clin Oncol 126 2000 153
5. Y. Aoyagi Y. Suzuki M. Isemura The fucosylation index of alpha-fetoprotein and its usefulness in the early diagnosis of hepatocellular carcinoma Cancer 61 1988 769
6. P. Arbuthnot M. Kew W. Fitschen c-fos And c-myc oncoprotein expression in human hepatocellular carcinomas Anticancer Res 11 1991 921
7. S. Arii E. Okamoto M. Imamura Registries in Japan: Current status of hepatocellular carcinoma in Japan. Liver Cancer Study Group of Japan Semin Surg Oncol 12 1996 204
8. R.L. Baron J.H. Oliver III G.D. Dodd III Hepatocellular carcinoma: Evaluation with biphasic, contrast-enhanced, helical CT Radiology 199 1996 505
9. M.M. Bern W. McDermott Jr B. Cady Intraaterial hepatic infusion and intravenous adriamycin for treatment of hepatocellular carcinoma: A clinical and pharmacology report Cancer 42 1978 399
10. E. Bernardinello L. Cavalletto L. Chemello Long-term clinical outcome after beta-interferon therapy in cirrhotic patients with chronic hepatitis C. TVVH Study Group Hepatogastroenterology 46 1999 3216
11. S. Boivin-Angele L. Lefrancois O. Froment Ras gene mutations in vinyl chloride-induced liver tumours are carcinogen-specific but vary with cell type and species Int J Cancer 85 2000 223
12. A.M. Bowcock M.R. Pinto E. Bey The PLC/PRF/5 human hepatoma cell line: II. Chromosomal assignment of hepatitis B virus integration sites Cancer Genet Cytogenet 18 1985 19
13. J. Breborowicz A. Mackiewicz D. Breborowicz Microheterogeneity of alpha-fetoprotein in patient serum as demonstrated by lectin affino-electrophoresis Scand J Immunol 14 1981 15
14. C. Brechot F. Degos C. Lugassy Hepatitis B virus DNA in patients with chronic liver disease and negative tests for hepatitis B surface antigen N Engl J Med 312 1985 270
15. B. Bressac M. Kew J. Wands Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa Nature 350 1991 429
16. F. Bussolino A. Albini G. Camussi Role of soluble mediators in angiogenesis Eur J Cancer 32A 1996 2401
17. Cancer of the Liver Italian Programme Tamoxifen in treatment of hepatocellular carcinoma: A randomised controlled trial. CLIP Group (Cancer of the Liver Italian Programme) Lancet 352 1998 17
18. American Joint Committee on Cancer Liver Cancer American Joint Committee AJCC Cancer Staging Handbook ed 5 1998 Lippincott–Williams & Wilkins Philadelphia 93
19. Capizzi RL, Hann HL, Feeney KJ, et al Gemcitabine, amifostine, and cisplatin (GAP) treatment for unresectable hepatocellular carcinoma (HCC) [abstract 1113]. In: Program/Proceedings of the 36th American Society of Clinical Oncology, New Orleans, 2000, p 285a
20. B.I. Carr J.C. Flickinger M.T. Lotze Hepatobiliary cancers V.T. DeVita S. Hellman S.A. Rosenberg Cancer, Principles and Practice of Oncology 1997 Lippincott-Raven Philadelphia 1087
21. M.H. Chang C.J. Chen M.S. Lai Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group N Engl J Med 336 1997 1855
22. C.J. Chen K.Y. Liang A.S. Chang Effects of hepatitis B virus, alcohol drinking, cigarette smoking and familial tendency on hepatocellular carcinoma Hepatology 13 1991 398
23. C.J. Chen M.W. Yu Y.F. Liaw Epidemiological characteristics and risk factors of hepatocellular carcinoma J Gastroenterol Hepatol 12 1997 S294
24. D.S. Chen G.C. Kuo J.L. Sung Hepatitis C virus infection in an area hyperendemic for hepatitis B and chronic liver disease: The Taiwan experience J Infect Dis 162 1990 817
25. A.L. Cheng Y.C. Chen K.H. Yeh Chronic oral etoposide and tamoxifen in the treatment of far-advanced hepatocellular carcinoma Cancer 77 1996 872
26. A.L. Cheng K.H. Yeh R.L. Fine Biochemical modulation of doxorubicin by high-dose tamoxifen in the treatment of advanced hepatocellular carcinoma Hepatogastroenterology 45 1998 1955
27. N.H. Chow P.I. Hsu X.Z. Lin Expression of vascular endothelial growth factor in normal liver and hepatocellular carcinoma: An immunohistochemical study Hum Pathol 28 1997 698
28. L.Y. Chuang W.C. Hung C.C. Chang Characterization of apoptosis induced by transforming growth factor beta 1 in human hepatoma cells Anticancer Res 14 1994 147
29. Y.H. Chung I.H. Song B.C. Song Combined therapy consisting of intraarterial cisplatin infusion and systemic interferon-alpha for hepatocellular carcinoma patients with major portal vein thrombosis or distant metastasis Cancer 88 2000 1986
30. Y.S. Chung K. Maeda M. Sowa Prognostic value of angiogenesis in gastro-intestinal tumours Eur J Cancer 32A 1996 2501
31. R. Colgrove G. Simon D. Ganem Transcriptional activation of homologous and heterologous genes by the hepatitis B virus x gene product in cells permissive for viral replication J Virol 63 1989 4019
32. M. Colombo R. de Franchis E. Del Ninno Hepatocellular carcinoma in Italian patients with cirrhosis N Engl J Med 325 1991 675
33. M. Cottone M. Turri M. Caltagirone Screening for hepatocellular carcinoma in patients with Child's A cirrhosis: An 8-year prospective study by ultrasound and alphafetoprotein J Hepatol 21 1994 1029
34. J.E. Dancey F.A. Shepherd Carcinoma of the liver J.F. Foley J.M. Vose J.O. Armitage Current Therapy in Cancer ed 2 1999 WB Saunders Philadelphia 81
35. A.T. De Souza G.R. Hankins M.K. Washington Frequent loss of heterozygosity on 6q at the mannose 6-phosphate/insulin-like growth factor II receptor locus in human hepatocellular tumors Oncogene 10 1995 1725
36. H. de The A. Marchio P. Tiollais A novel steroid thyroid hormone receptor-related gene inappropriately expressed in human hepatocellular carcinoma Nature 330 1987 667
37. A.M. Di Bisceglie Hepatocellular carcinoma: Molecular biology of its growth and relationship to hepatitis B virus infection Med Clin North Am 73 1989 985
38. L. Diaz-Flores R. Gutierrez H. Varela Angiogenesis: An update Histol Histopathol 9 1994 807
39. J.L. Dienstag Non-A, non-B hepatitis: I. Recognition, epidemiology, and clinical features Gastroenterology 85 1983 439
40. S.F. Ding N.A. Habib J. Dooley Loss of constitutional heterozygosity on chromosome 5q in hepatocellular carcinoma without cirrhosis Br J Cancer 64 1991 1083
41. M. Ebara M. Ohto T. Shinagawa Natural history of minute hepatocellular carcinoma smaller than three centimeters complicating cirrhosis. A study in 22 patients Gastroenterology 90 1986 289
42. H.A. Edmondson P.E. Steiner Primary carcinoma of the liver Cancer 7 1954 462
43. T. Eisen C. Boshoff I. Mak Continuous low dose thalidomide: a phase II study in advanced melanoma, renal cell, ovarian and breast cancer Br J Cancer 82 2000 812
44. O.N. El-Assal A. Yamanoi Y. Soda Clinical significance of microvessel density and vascular endothelial growth factor expression in hepatocellular carcinoma and surrounding liver: Possible involvement of vascular endothelial growth factor in the angiogenesis of cirrhotic liver Hepatology 27 1998 1554
45. O.N. el-Assal A. Yamanoi Y. Soda Proposal of invasiveness score to predict recurrence and survival after curative hepatic resection for hepatocellular carcinoma Surgery 122 1997 571
46. M. Emi Y. Fujiwara T. Nakajima Frequent loss of heterozygosity for loci on chromosome 8p in hepatocellular carcinoma, colorectal cancer, and lung cancer Cancer Res 52 1992 5368
47. P.F. Engstrom B. Levin C.G. Moertel A phase II trial of tamoxifen in hepatocellular carcinoma Cancer 65 1990 2641
48. P.F. Engstrom K. McGlynn J.P. Hoffman Primary neoplasms of the liver J.F. Hollan R.C. Bast D.L. Morton Cancer Medicine ed 3 1997 Williams & Wilkins Baltimore 1923
49. D.M. Evans W.J. Williams I.T. Kung Angiosarcoma and hepatocellular carcinoma in vinyl chloride workers Histopathology 7 1983 377
50. C. Fabris D.A. Basso G. Leandro Serum CA 19-9 and alpha-fetoprotein levels in primary hepatocellular carcinoma and liver cirrhosis Cancer 68 1991 1795
51. G. Falkson B.J. Coetzer Phase II studies of mitoxantrone in patients with primary liver cancer Invest New Drugs 3 1985 187
52. G.C. Farrell D.E. Joshua R.F. Uren Androgen-induced hepatoma Lancet 1 1975 430
53. R.L. Fisher L. Taylor S. Sherlock Alpha-1-antitrypsin deficiency in liver disease: The extent of the problem Gastroenterology 71 1976 646
54. J. Folkman Tumor angiogenesis: Therapeutic implications N Engl J Med 285 1971 1182
55. J. Folkman Angiogenesis in cancer, vascular, rheumatoid and other disease Nat Med 1 1995 27
56. J. Folkman Y. Shing Angiogenesis J Biol Chem 267 1992 10931
57. G. Fourel C. Trepo L. Bougueleret Frequent activation of N-myc genes by hepadnavirus insertion in woodchuck liver tumours Nature 347 1990 294
58. B. Fremond H. Jouan A.H. Sameh Tumors of the liver secondary to androgen therapy. Apropos of 2 cases in children Chir Pediatr 28 1987 97
59. M.A. Friedman Primary hepatocellular cancer–present results and future prospects Int J Radiat Oncol Biol Phys 9 1983 1841
60. M. Fujimori T. Tokino O. Hino Allelotype study of primary hepatocellular carcinoma Cancer Res 51 1991 89
61. Fuloria J, Parikh PM, Prabhakaran M, et al. A multicenter, phase II trial of gemcitabine and cisplatin in unresectable hepatocellular carcinoma [abstract 1143]. In Program/Proceedings of the 36th American Society of Clinical Oncology, New Orleans, 2000, p 292a
62. D. Ganem H.E. Varmus The molecular biology of the hepatitis B viruses Annu Rev Biochem 56 1987 651
63. G. Gasparini Clinical significance of the determination of angiogenesis in human breast cancer: Update of the biological background and overview of the Vicenza studies Eur J Cancer 32A 1996 2485
64. J.R. Gu Molecular aspects of human hepatic carcinogenesis Carcinogenesis 9 1988 697
65. A.J. Hanley B.C. Choi E.J. Holowaty Cancer mortality among Chinese migrants: A review Int J Epidemiol 24 1995 255
66. C.B. Harley B. Villeponteau Telomeres and telomerase in aging and cancer Curr Opin Genet Dev 5 1995 249
67. Hassan MM, Patt YZ, Lozano RD, et al. Continuous I.V. Infusion of 5-FU and subcutaneous recombinant interferon alpha 2b is an active regimen in fibrolamellar hepatocellular carcinoma [abstract 1222]. In Program/Proceedings of the 36th American Society of Clinical Oncology, New Orleans, 2000, p 310a
68. B.E. Henderson S. Preston-Martin H.A. Edmondson Hepatocellular carcinoma and oral contraceptives Br J Cancer 48 1983 437
69. O. Hino T. Kitagawa K. Koike Detection of hepatitis B virus DNA in hepatocellular carcinomas in Japan Hepatology 4 1984 90
70. H.S. Hochster M.D. Green J. Speyer 4′Epidoxorubicin (epirubicin): Activity in hepatocellular carcinoma J Clin Oncol 3 1985 1535
71. H.C. Hollingsworth E.C. Kohn S.M. Steinberg Tumor angiogenesis in advanced stage ovarian carcinoma Am J Pathol 147 1995 33
72. H. Honda T. Tajima K. Kajiyama Vascular changes in hepatocellular carcinoma: Correlation of radiologic and pathologic findings AJR Am J Roentgenol 173 1999 1213
73. C.C. Hsia C.A. Axiotis A.M. Di Bisceglie Transforming growth factor-alpha in human hepatocellular carcinoma and coexpression with hepatitis B surface antigen in adjacent liver Cancer 70 1992 1049
74. I.C. Hsu R.A. Metcalf T. Sun Mutational hotspot in the p53 gene in human hepatocellular carcinomas Nature 350 1991 427
75. I.C. Hsu T. Tokiwa W. Bennett p53 Gene mutation and integrated hepatitis B viral DNA sequences in human liver cancer cell lines Carcinogenesis 14 1993 987
76. T. Hsu T. Moroy J. Etiemble Activation of c-myc by woodchuck hepatitis virus insertion in hepatocellular carcinoma Cell 55 1988 627
77. K. Ikeda Y. Arase S. Saitoh Interferon beta prevents recurrence of hepatocellular carcinoma after complete resection or ablation of the primary tumor—a prospective randomized study of hepatitis C virus-related liver cancer Hepatology 32 2000 228
78. K. Ikeda S. Saitoh Y. Arase Effect of interferon therapy on hepatocellular carcinogenesis in patients with chronic hepatitis type C: A long-term observation study of 1,643 patients using statistical bias correction with proportional hazard analysis Hepatology 29 1999 1124
79. K. Ikeda S. Saitoh Y. Suzuki Interferon decreases hepatocellular carcinogenesis in patients with cirrhosis caused by the hepatitis B virus: A pilot study Cancer 82 1998 827
80. T. Ito Y. Sasaki J.R. Wands Overexpression of human insulin receptor substrate 1 induces cellular transformation with activation of mitogen-activated protein kinases Mol Cell Biol 16 1996 943
81. S. Iwatsuki T.E. Starzl D.G. Sheahan Hepatic resection versus transplantation for hepatocellular carcinoma Ann Surg 214 1991 221
82. K. Jaskiewicz L. Banach E. Izycka Hepatocellular carcinoma in young patients: Histology, cellular differentiation, HBV infection and oncoprotein p53 Anticancer Res 15 1995 2723
83. Javed AA, Gurchani SA, Masud AI. Tamoxifen and radiotherapy in advance unresectable hepatocellular carcinoma [abstract 1119]. In Program/Proceedings of the 36th American Society of Clinical Oncology, New Orleans, 2000, p 286a
84. F.L. Johnson K.G. Lerner M. Siegel Association of androgenic-anabolic steroid therapy with development of hepatocellular carcinoma Lancet 2 1972 1273
85. M. Kajanti S. Pyrhonen M. Mantyla Intra-arterial and intravenous use of 4′ epidoxorubicin combined with 5-fluorouracil in primary hepatocellular carcinoma: A randomized comparison Am J Clin Oncol 15 1992 37
86. M. Kajanti P. Rissanen P. Virkkunen Regional intra-arterial infusion of cisplatin in primary hepatocellular carcinoma. A phase II study Cancer 58 1986 2386
87. T. Kanematsu T. Furuta K. Takenaka A 5-year experience of lipiodolization: Selective regional chemotherapy for 200 patients with hepatocellular carcinoma Hepatology 10 1989 98
88. A. Kasahara N. Hayashi K. Mochizuki Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C. Osaka Liver Disease Study Group Hepatology 27 1998 1394
89. S. Katiyar B.C. Dash V. Thakur p53 Tumor suppressor gene mutations in hepatocellular carcinoma patients in India Cancer 88 2000 1565
90. I. Kato C. Kido Increased risk of death in Thorotrast-exposed patients during the late follow-up period Jpn J Cancer Res 78 1987 1187
91. H. Kawai T. Suda Y. Aoyagi Quantitative evaluation of genomic instability as a possible predictor for development of hepatocellular carcinoma: Comparison of loss of heterozygosity and replication error Hepatology 31 2000 1246
92. A.S. Kekule U. Lauer M. Meyer The preS2/S region of integrated hepatitis B virus DNA encodes a transcriptional transactivator Nature 343 1990 457
93. H. Kim M.J. Lee M.R. Kim Expression of cyclin D1, cyclin E, cdk4 and loss of heterozygosity of 8p, 13q, 17p in hepatocellular carcinoma: Comparison study of childhood and adult hepatocellular carcinoma Liver 20 2000 173
94. M. Kin T. Torimura T. Ueno Angiogenesis inhibitor TNP-470 suppresses the progression of experimentally-induced hepatocellular carcinoma in rats Int J Oncol 16 2000 375
95. G.D. Kirk A.M. Camus-Randon M. Mendy Ser-249 p53 mutations in plasma DNA of patients with hepatocellular carcinoma from the Gambia J Natl Cancer Inst 92 2000 148
96. Y. Kondo Y. Niwa B. Akikusa A histopathologic study of early hepatocellular carcinoma Cancer 52 1983 687
97. E. Kouroumalis P. Skordilis K. Thermos Treatment of hepatocellular carcinoma with octreotide: A randomised controlled study Gut 42 1998 442
98. T. Kuroki Y. Fujiwara E. Tsuchiya Accumulation of genetic changes during development and progression of hepatocellular carcinoma: Loss of heterozygosity of chromosome arm 1p occurs at an early stage of hepatocarcinogenesis Genes Chromosomes Cancer 13 1995 163
99. C.L. Lai P.C. Wu G.C. Chan Doxorubicin versus no antitumor therapy in inoperable hepatocellular carcinoma. A prospective randomized trial Cancer 62 1988 479
100. T.A. Landers H.B. Greenberg W.S. Robinson Structure of hepatitis B Dane particle DNA and nature of the endogenous DNA polymerase reaction J Virol 23 1977 368
101. G.H. Leder J. Pillasch M. Kornmann Theoretical considerations and in vitro concentration response studies with two human colorectal carcinoma cell lines. The rational experimental base for clinical studies in regional chemotherapy Gan To Kagaku Ryoho 27 2000 565
102. 1 injection J Hepatol 5 1987 27
103. U. Leonhardt U. Ritzel M. Ottleben Detection of circulating albumin-mRNA by RT-PCR does not indicate metastasizing hepatocellular carcinoma Langenbecks Archir fur Chirurgie 382 1997 83
104. D.W. Leung G. Cachianes W.J. Kuang Vascular endothelial growth factor is a secreted angiogenic mitogen Science 246 1989 1306
105. T.W. Leung Y.Z. Patt W.Y. Lau Complete pathological remission is possible with systemic combination chemotherapy for inoperable hepatocellular carcinoma Clin Cancer Res 5 1999 1676
106. M. Levrero C. Balsano M.L. Avantaggiati Hepatitis B virus and hepatocellular carcinoma: A possible role for the viral transactivators Italian Journal of Gastroenterology 23 1991 576
107. C.S. Lieber A. Garro M.A. Leo Alcohol and cancer Hepatology 6 1986 1005
108. H.A. Liebman B.C. Furie M.J. Tong Des-gamma-carboxy (abnormal) prothrombin as a serum marker of primary hepatocellular carcinoma N Engl J Med 310 1984 1427
109. D.Y. Lin S.M. Lin Y.F. Liaw Non-surgical treatment of hepatocellular carcinoma J Gastroenterol Hepatol 12 1997 S319
110. J. Lin W. Shiu W.T. Leung Phase II study of high-dose ifosfamide in hepatocellular carcinoma Cancer Chemother Pharmacol 31 1993 338
111. M. Lisker-Melman P. Martin J.H. Hoofnagle Conditions associated with hepatocellular carcinoma Med Clin North Am 73 1989 999
112. Lozano RD, Patt TZ, Hassan MM, et al. Oral capecitabine (Xeloda) for the treatment of hepatobiliary cancers (hepatocellular carcinoma, cholangiocarcinoma, and gallblader cancer) [abstract 1025]. In Program/Proceedings of the 36th American Society of Clinical Oncology, New Orleans, 2000, p 264a
113. S.N. Lu T.M. Lin C.J. Chen A case-control study of primary hepatocellular carcinoma in Taiwan Cancer 62 1988 2051
114. V.M. Macaulay Insulin-like growth factors and cancer Br J Cancer 65 1992 311
115. R.N. MacSween Alcohol and cancer Br Med Bull 38 1982 31
116. Y. Maehara Y. Kakeji S. Ohno Scientific basis for the combination of tegafur with uracil Oncology (Huntingt) 11 1997 14
117. A.E. Mahfouz B. Hamm M. Taupitz Contrast agents for MR imaging of the liver: A clinical overview Eur Radiol 7 1997 507
118. I.A. Malik W.A. Khan S. Haq A prospective phase II trial to evaluate the efficacy and toxicity of hepatic arterial infusion of ifosfamide in patients with inoperable localized hepatocellular carcinoma Am J Clin Oncol 20 1997 289
119. S. Mani D. Sciortino B. Samuels Phase II trial of uracil/tegafur (UFT) plus leucovorin in patients with advanced biliary carcinoma Invest New Drugs 17 1999 97
120. O. Matsui M. Kadoya T. Kameyama Benign and malignant nodules in cirrhotic livers: Distinction based on blood supply Radiology 178 1991 493
121. W.M. Melia P.J. Johnson S. Carter Plasma carcinoembryonic antigen in the diagnosis and management of patients with hepatocellular carcinoma Cancer 48 1981 1004
122. W.M. Melia P.J. Johnson R. Williams Induction of remission in hepatocellular carcinoma. A comparison of VP 16 with adriamycin Cancer 51 1983 206
123. W.M. Melia D. Westaby R. Williams Diamminodichloride platinum (cis-platinum) in the treatment of hepatocellular carcinoma Clin Oncol 7 1981 275
124. M. Meyer K.H. Wiedorn P.H. Hofschneider A chromosome 17:7 translocation is associated with a hepatitis B virus DNA integration in human hepatocellular carcinoma DNA Hepatology 15 1992 665
125. R. Montesano J.D. Vassalli A. Baird Basic fibroblast growth factor induces angiogenesis in vitro Proc Natl Acad Sci U S A 83 1986 7297
126. K. Mori M. Hasegawa M. Nishida Expression levels of thymidine phosphorylase and dihydropyrimidine dehydrogenase in various human tumor tissues Int J Oncol 17 2000 33
127. J.J. Mulvihill R.L. Ridolfi F.R. Schultz Hepatic adenoma in Fanconi anemia treated with oxymetholone J Pediatr 87 1975 122
128. K. Murakami T. Matsuura S. Hasumura Involvement of insulin-like growth factor binding protein-3 in the retinoic acid receptor-alpha-mediated inhibition of hepatocellular carcinoma cell proliferation Cancer Lett 151 2000 63
129. Y. Murakami K. Hayashi S. Hirohashi Aberrations of the tumor suppressor p53 and retinoblastoma genes in human hepatocellular carcinomas Cancer Res 51 1991 5520
130. Y. Muto H. Moriwaki M. Ninomiya Prevention of second primary tumors by an acyclic retinoid, polyprenoic acid, in patients with hepatocellular carcinoma. Hepatoma Prevention Study Group N Engl J Med 334 1996 1561
131. O. Nakashima S. Sugihara M. Kage Pathomorphologic characteristics of small hepatocellular carcinoma: A special reference to small hepatocellular carcinoma with indistinct margins Hepatology 22 1995 101
132. N. Nishida Y. Fukuda H. Kokuryu Accumulation of allelic loss on arms of chromosomes 13q, 16q and 17p in the advanced stages of human hepatocellular carcinoma Int J Cancer 51 1992 862
133. S. Nishiguchi T. Kuroki S. Nakatani Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis Lancet 346 1995 1051
134. N. Ogata T. Kamimura H. Asakura Point mutation, allelic loss and increased methylation of c-Ha-ras gene in human hepatocellular carcinoma Hepatology 13 1991 31
135. M. Ohto M. Yoshikawa H. Saisho Nonsurgical treatment of hepatocellular carcinoma in cirrhotic patients World J Surg 19 1995 42
136. H. Oka A. Tamori T. Kuroki Prospective study of alpha-fetoprotein in cirrhotic patients monitored for development of hepatocellular carcinoma Hepatology 19 1994 61
137. K. Okuda Hepatocellular carcinoma J Hepatol 32 2000 225
138. K. Okuda H. Obata Y. Nakajima Prognosis of primary hepatocellular carcinoma Hepatology 4 1984 3S
139. K. Okuda T. Ohtsuki H. Obata Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients Cancer 56 1985 918
140. S. Onohara H. Kobayashi Y. Itoh Intra-arterial cis-platinum infusion with sodium thiosulfate protection and angiotensin II induced hypertension for treatment of hepatocellular carcinoma Acta Radiol 29 1988 197
141. 90Yttrium antiferritin–a new therapeutic radiolabeled antibody Int J Radiat Oncol Biol Phys 12 1986 277
142. M. Ozturk p53 Mutation in hepatocellular carcinoma after aflatoxin exposure Lancet 338 1991 1356
143. U.S. Park J.J. Su K.C. Ban Mutations in the p53 tumor suppressor gene in tree shrew hepatocellular carcinoma associated with hepatitis B virus infection and intake of aflatoxin B1 Gene 251 2000 73
144. D. Pateron N. Ganne J.C. Trinchet Prospective study of screening for hepatocellular carcinoma in Caucasian patients with cirrhosis J Hepatol 20 1994 65
145. Y.Z. Patt M.M. Hassan R.D. Lozano Durable clinical response of refractory hepatocellular carcinoma to orally administered thalidomide Am J Clin Oncol 23 2000 319
146. Patt YZ, Hassan MM, Lozano RD, et al. Phase II trial of thalomid (thalidomide) for treatment of non-resectable hepatocellular carcinoma [abstract 1035]. In Program/Proceedings of the 36th American Society of Clinical Oncology, New Orleans, 2000, p 266a
147. Y.Z. Patt A. Hoque M. Roh Durable clinical and pathologic response of hepatocellular carcinoma to systemic and hepatic arterial administration of platinol, recombinant interferon alpha 2b, doxorubicin, and 5-fluorouracil: A communication Am J Clin Oncol 22 1999 209
148. Y.Z. Patt B. Yoffe C. Charnsangavej Low serum alpha-fetoprotein level in patients with hepatocellular carcinoma as a predictor of response to 5-FU and interferon-alpha-2b Cancer 72 1993 2574
149. R. Pazdur Phase I and pharmacokinetic evaluations of UFT plus oral leucovorin Oncology (Huntingt) 11 1997 35
150. R. Pazdur Phase II study of UFT plus leucovorin in colorectal cancer Oncology 54 1997 19
151. R. Pazdur UFT: East meets West in drug development Oncology (Huntingt) 11 1997 11
152. G. Pelletier A. Roche O. Ink A randomized trial of hepatic arterial chemoembolization in patients with unresectable hepatocellular carcinoma J Hepatol 11 1990 181
153. I. Penn Hepatic transplantation for primary and metastatic cancers of the liver Surgery 110 1991 726
154. J.C. Reubi A. Zimmermann S. Jonas Regulatory peptide receptors in human hepatocellular carcinomas Gut 45 1999 766
155. S. Riestra M. Rodriguez M. Delgado Tamoxifen does not improve survival of patients with advanced hepatocellular carcinoma J Clin Gastroenterol 26 1998 200
156. B. Ringe R. Pichlmayr C. Wittekind Surgical treatment of hepatocellular carcinoma: Experience with liver resection and transplantation in 198 patients World J Surg 15 1991 270
157. C.E. Rogler M. Sherman C.Y. Su Deletion in chromosome 11p associated with a hepatitis B integration site in hepatocellular carcinoma Science 230 1985 319
158. E. Rummeny R. Weissleder D.D. Stark Primary liver tumors: Diagnosis by MR imaging AJR Am J Roentgenol 152 1989 63
159. M. Sakon M. Monden M. Gotoh The effects of vitamin K on the generation of des-gamma-carboxy prothrombin (PIVKA-II) in patients with hepatocellular carcinoma Am J Gastroenterol 86 1991 339
160. G. Schachschal H. Lochs M. Plauth Controlled clinical trial of doxorubicin and tamoxifen versus tamoxifen monotherapy in hepatocellular carcinoma Eur J Gastroenterol Hepatol 12 2000 281
161. D. Schottenfeld Alcohol as a co-factor in the etiology of cancer Cancer 43 1979 1962
162. D.A. Shafritz D. Shouval H.I. Sherman Integration of hepatitis B virus DNA into the genome of liver cells in chronic liver disease and hepatocellular carcinoma. Studies in percutaneous liver biopsies and post-mortem tissue specimens N Engl J Med 305 1981 1067
163. F.A. Shepherd W.K. Evans M.E. Blackstein Hepatic arterial infusion of mitoxantrone in the treatment of primary hepatocellular carcinoma J Clin Oncol 5 1987 635
164. J.C. Sheu Molecular mechanism of hepatocarcinogenesis J Gastroenterol Hepatol 12 1997 S309
165. J.C. Sheu G.T. Huang L.N. Shih Hepatitis C and B viruses in hepatitis B surface antigen-negative hepatocellular carcinoma Gastroenterology 103 1992 1322
166. J.C. Sheu J.L. Sung D.S. Chen Early detection of hepatocellular carcinoma by real-time ultrasonography. A prospective study Cancer 56 1985 660
167. J.C. Sheu J.L. Sung D.S. Chen Ultrasonography of small hepatic tumors using high-resolution linear-array real-time instruments Radiology 150 1984 797
168. J.C. Sheu J.T. Wang T.H. Wang Prevalence of hepatitis C viral infection in a community in Taiwan: Detection by synthetic peptide-based assay and polymerase chain reaction J Hepatol 17 1993 192
169. M. Shiraishi S. Morinaga M. Noguchi Loss of genes on the short arm of chromosome 11 in human lung carcinomas Jpn J Cancer Res 78 1987 1302
170. Y. Soini S.C. Chia W.P. Bennett An aflatoxin-associated mutational hotspot at codon 249 in the p53 tumor suppressor gene occurs in hepatocellular carcinomas from Mexico Carcinogenesis 17 1996 1007
171. D.F. Spandau C.H. Lee Trans-activation of viral enhancers by the hepatitis B virus X protein J Virol 62 1988 427
172. K. Stuart J. Tessitore M. Huberman 5-Fluorouracil and alpha-interferon in hepatocellular carcinoma Am J Clin Oncol 19 1996 136
173. S.O. Stuver H. Kuper A. Tzonou Insulin-like growth factor 1 in hepatocellular carcinoma and metastatic liver cancer in men Int J Cancer 87 2000 118
174. Q. Su C.H. Schroder G. Otto Overexpression of p53 protein is not directly related to hepatitis B x protein expression and is associated with neoplastic progression in hepatocellular carcinomas rather than hepatic preneoplasia Mutat Res 462 2000 365
175. K. Suzuki Y. Hirooka S. Tsujitani Relationship between loss of heterozygosity at microsatellite loci and computerized nuclear morphometry in hepatocellular carcinoma Anticancer Res 20 2000 1257
176. H. Tahara T. Nakanishi M. Kitamoto Telomerase activity in human liver tissues: Comparison between chronic liver disease and hepatocellular carcinomas Cancer Res 55 1995 2734
177. K. Takayasu H. Furukawa F. Wakao CT diagnosis of early hepatocellular carcinoma: Sensitivity, findings, and CT-pathologic correlation AJR Am J Roentgenol 164 1995 885
178. K. Takayasu F. Wakao N. Moriyama Response of early-stage hepatocellular carcinoma and borderline lesions to therapeutic arterial embolization AJR Am J Roentgenol 160 1993 301
179. A. Takenaka K. Komori T. Morishita Amino acid regulation of gene transcription of rat insulin-like growth factor-binding protein-1 J Endocrinol 164 2000 R11
180. K. Taketa C. Sekiya M. Namiki Lectin-reactive profiles of alpha-fetoprotein characterizing hepatocellular carcinoma and related conditions Gastroenterology 99 1990 508
181. Y. Tanabe K. Ohnishi F. Nomura Plasma abnormal prothrombin levels in patients with small hepatocellular carcinoma Am J Gastroenterol 83 1988 1386
182. S. Tanaka T. Kitamra M. Fujita Small hepatocellular carcinoma: Differentiation from adenomatous hyperplastic nodule with color Doppler flow imaging Radiology 182 1992 161
183. J.G. Teeguarden M.A. Newton Y.P. Dragan Genome-wide loss of heterozygosity analysis of chemically induced rat hepatocellular carcinomas reveals elevated frequency of allelic imbalances on chromosomes 1, 6, 8, 11, 15, 17, and 20 Mol Carcinog 28 2000 51
184. T. Teramoto K. Satonaka S. Kitazawa p53 Gene abnormalities are closely related to hepatoviral infections and occur at a late stage of hepatocarcinogenesis Cancer Res 54 1994 231
185. S. Thongprasert K. Klunklin K. Phornphutkul Phase II study of ifosfamide (Holoxan) in hepatoma Eur J Cancer Clin Oncol 24 1988 1795
186. P. Tiollais C. Pourcel A. Dejean The hepatitis B virus Nature 317 1985 489
187. T. Tokino S. Fukushige T. Nakamura Chromosomal translocation and inverted duplication associated with integrated hepatitis B virus in hepatocellular carcinomas J Virol 61 1987 3848
188. H. Tsukuma T. Hiyama S. Tanaka Risk factors for hepatocellular carcinoma among patients with chronic liver disease N Engl J Med 328 1993 1797
189. G. van Kaick H. Wesch H. Luhrs Radiation-induced primary liver tumors in “Thorotrast patients” Recent Results Cancer Res 100 1986 16
190. I.C. Weitz H.A. Liebman Des-gamma-carboxy (abnormal) prothrombin and hepatocellular carcinoma: A critical review Hepatology 18 1993 990
191. C.P. Wild F. Yin P.C. Turner Environmental and genetic determinants of aflatoxin-albumin adducts in the Gambia Int J Cancer 86 2000 1
192. O. Yokosuka M. Omata F. Imazeki Hepatitis B virus RNA transcripts and DNA in chronic liver disease N Engl J Med 315 1986 1187
193. E.D. Yorke A. Jackson R.A. Fox Can current models explain the lack of liver complications in Y-90 microsphere therapy? Clin Cancer Res 5 1999 3024s
194. N.N. Zein Interferons in the management of viral hepatitis Cytokines Cell Mol Ther 4 1998 229
195. X.D. Zhou Z.Y. Tang Y.Q. Yu Clinical evaluation of cryosurgery in the treatment of primary liver cancer. Report of 60 cases Cancer 61 1988 1889
196. Y.Z. Zhou B.L. Slagle L.A. Donehower Structural analysis of a hepatitis B virus genome integrated into chromosome 17p of a human hepatocellular carcinoma J Virol 62 1988 4224